Heska Co. (NASDAQ:HSKA) Given Average Rating of “Buy” by Analysts

Shares of Heska Co. (NASDAQ:HSKAGet Rating) have been given an average rating of “Hold” by the eight research firms that are presently covering the firm, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $205.20.

HSKA has been the topic of a number of recent analyst reports. TheStreet lowered shares of Heska from a “c-” rating to a “d+” rating in a research report on Friday, February 11th. Morgan Stanley reduced their target price on Heska from $190.00 to $161.00 and set an “equal weight” rating for the company in a report on Tuesday, March 1st. Zacks Investment Research raised Heska from a “strong sell” rating to a “hold” rating in a research report on Tuesday, May 24th. StockNews.com assumed coverage on Heska in a research report on Thursday, March 31st. They issued a “hold” rating on the stock. Finally, Piper Sandler lowered their target price on Heska from $190.00 to $180.00 and set a “na” rating on the stock in a research note on Sunday, May 15th.

HSKA stock opened at $98.85 on Thursday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 5.37 and a current ratio of 6.73. Heska has a twelve month low of $82.92 and a twelve month high of $275.94. The stock’s 50 day moving average is $114.29 and its 200-day moving average is $137.97.

Heska (NASDAQ:HSKAGet Rating) last released its quarterly earnings results on Monday, May 9th. The medical research company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.30). The company had revenue of $64.80 million during the quarter, compared to analysts’ expectations of $66.32 million. Heska had a negative net margin of 5.04% and a negative return on equity of 0.95%. The company’s quarterly revenue was up 7.1% compared to the same quarter last year. During the same period in the previous year, the company posted $0.20 earnings per share. As a group, equities analysts predict that Heska will post 0.29 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Voya Investment Management LLC boosted its holdings in shares of Heska by 1.7% in the third quarter. Voya Investment Management LLC now owns 3,740 shares of the medical research company’s stock worth $967,000 after acquiring an additional 62 shares during the period. Maryland State Retirement & Pension System lifted its position in Heska by 1.9% during the fourth quarter. Maryland State Retirement & Pension System now owns 4,270 shares of the medical research company’s stock valued at $779,000 after purchasing an additional 81 shares during the last quarter. Rhumbline Advisers increased its holdings in shares of Heska by 0.4% in the 4th quarter. Rhumbline Advisers now owns 23,386 shares of the medical research company’s stock worth $4,268,000 after buying an additional 85 shares during the last quarter. Louisiana State Employees Retirement System lifted its holdings in shares of Heska by 2.0% during the 4th quarter. Louisiana State Employees Retirement System now owns 5,200 shares of the medical research company’s stock worth $949,000 after acquiring an additional 100 shares during the last quarter. Finally, Thrivent Financial for Lutherans lifted its stake in Heska by 1.3% during the fourth quarter. Thrivent Financial for Lutherans now owns 8,717 shares of the medical research company’s stock worth $1,591,000 after purchasing an additional 113 shares during the last quarter. 95.94% of the stock is currently owned by institutional investors and hedge funds.

Heska Company Profile (Get Rating)

Heska Corporation sells veterinary and animal health diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Mexico, Australia, France, Germany, Italy, Malaysia, Spain, and Switzerland. The company offers Element DC, Element DCX, Element DC5x veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element RC, Element RCX, and Element RC3X chemistry systems for blood chemistry and electrolyte analysis; Element HT5 and scil Vet abc Plus veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; and Element COAG and Element AIM veterinary analyzers.

Further Reading

Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.